M&A Deal Summary

Dyax Acquires Target Quest BV

On August 4, 1999, Dyax acquired life science company Target Quest BV

Acquisition Highlights
  • This is Dyax’s 1st transaction in the Life Science sector.
  • This is Dyax’s 1st transaction in the Netherlands.

M&A Deal Summary

Date 1999-08-04
Target Target Quest BV
Sector Life Science
Buyer(s) Dyax
Deal Type Add-on Acquisition

Target

Target Quest BV

Netherlands
Target Quest is a biotechnology company specializing in the application of Phage Display technology for antibody engineering and discovery of novel cancer therapeutics, the company announced today.

Search 177,829 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Dyax

Burlington, Massachusetts, United States

website


Category Company
Founded 1989
Sector Life Science
Employees124
Revenue 82M USD (2014)
DESCRIPTION

Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, a fully human monoclonal antibody, for the prevention of HAE attacks. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Netherlands) 1 of 1
Year (1999) 1 of 1